Chronic myelogenous leukemia stem cells: What's new?

Current Hematologic Malignancy Reports

Volumn 4, Issue 2, 2009, Pages 66-73

  Copland, Mhairi ^a  

^a GARTNAVEL GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 BENZYL 7 CYANO 2,3,4,5 TETRAHYDRO 1 (1H IMIDAZOL 4 YLMETHYL) 4 (2 THIENYLSULFONYL) 1H 1,4 BENZODIAZEPINE; ABELSON HELPER INTEGRATION SITE 1; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; BCR ABL PROTEIN; BETA CATENIN; BMS 225975; CHEMOKINE RECEPTOR CXCR4; FINGOLIMOD; HISTONE DEACETYLASE INHIBITOR; IMATINIB; ONCOPROTEIN; PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEIN TYROSINE KINASE INHIBITOR; RNA BINDING PROTEIN; SONIC HEDGEHOG PROTEIN; TUMOR SUPPRESSOR PROTEIN; TUMOR SUPPRESSOR PROTEIN PHOSPHATASE 2A; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER STEM CELL; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL POPULATION; CELL PROLIFERATION; CELL RENEWAL; CHRONIC MYELOID LEUKEMIA; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; HUMAN; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; REVIEW; TARGET CELL DESTRUCTION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZODIAZEPINES; CELL LINEAGE; HEMATOPOIETIC STEM CELLS; HUMANS; IMIDAZOLES; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MODELS, BIOLOGICAL; NEOPLASTIC STEM CELLS; PROTEIN KINASE INHIBITORS; TREATMENT OUTCOME;

EID: 63549121688     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-009-0010-9     Document Type: Review

References (51)

1. RoAley JD: Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973, 243:290-293.
2. Savona M, Talpaz M: Getting to the stem of chronic myeloid leukaemia. Nat Rev Cancer 2008, 8:341-350.
3. Wang JC, Lapidot T, Cashman JD, et al.: High level engraftment of NOD/ SCID mice by primitive normal and leukemic hematopoietic cells from patients with chronic myeloid leukemia in chronic phase. Blood 1998, 91:2406-2414.
4. Holyoake T, Jiang X, Eaves C, Eaves A: Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. Blood 1999, 94:2056-2064.
5. Copland M, Hamilton A, Elrick LJ, et al.: Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML, but does not eliminate the quiescent fraction. Blood 2006, 107:4532-4539.
6. Graham SM, Jorgensen HG, Allan E, et al.: Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002, 99:319-325.
7. Jorgensen HG, Allan EK, Jordanides NE, et al.: Nilotinib exerts equipotent anti-proliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells. Blood 2007, 109:4016-4019.
8. Konig H, Holyoake TL, Bhatia R: Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606. Blood 2008, 111:2329-2338.
9. Jamieson CH, Ailles LE, Dylla SJ, et al.: Granulocytemacrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 2004, 351:657-667.
10. Druker BJ, Guilhot F, O'Brien SG, et al.: Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006, 355:2408-2417.
11. Kantarjian H, Giles F, Wunderle L, et al.: Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006, 354:2542-2551.
12. Talpaz M, Shah NP, Kantarjian H, et al.: Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006, 354:2531-2541.
13. Hughes TP, Kaeda J, Branford S, et al.: Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003, 349:1423-1432.
14. Branford S, Rudzki Z, Grigg A, et al.: BCR-ABL levels continue to decrease up to 42 months after commencement of standard dose imatinib in patients with newly diagnosed chronic phase CML who achieve a molecular response. Blood 2004, 104:82a.
15. Bhatia R, Holtz M, Niu N, et al.: Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 2003, 101:4701-4707.
16. Zhou LL, Zhao Y, Ringrose A, et al.: AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells. J Exp Med 2008, 205:2657-2671.
17. Jiang X, Zhao Y, Chan WY, et al.: Deregulated expression in Ph+ human leukemias of AHI-1, a gene activated by insertional mutagenesis in mouse models of leukemia. Blood 2004, 103:3897-3904.
18. Ito K, Bernardi R, Morotti A, et al.: PML targeting eradicates quiescent leukaemia-initiating cells. Nature 2008, 453:1072-1078.
19. Jin L, Tabe Y, Konoplev S, et al.: CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells. Mol Cancer Ther 2008, 7:48-58.
20. Nie Y, Han YC, Zou YR: CXCR4 is required for the quiescence of primitive hematopoietic cells. J Exp Med 2008, 205:777-783.
21. Geay JF, Buet D, Zhang Y, et al.: P210BCR-ABL inhibits SDF-1 chemotactic response via alteration of CXCR4 signaling and down-regulation of CXCR4 expression. Cancer Res 2005, 65:2676-2683.
22. Eiring AM, Neviani P, Santhanam R, et al.: Identification of novel posttranscriptional targets of the BCR/ABL oncoprotein by ribonomics: requirement of E2F3 for BCR/ABL leukemogenesis. Blood 2008, 111:816-828.
23. Perrotti D, Neviani P: From mRNA mCtabolism to cancer therapy: chronic myelogenous leukemia shows the way. Clin Cancer Res 2007, 13:1638-1642.
24. Zhao C, Blum J, Chen A, et al.: Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo. Cancer Cell 2007, 12:528-541.
25. Minami Y, Stuart SA, Ikawa T, et al.: BCR-ABL-transformed GMP as myeloid leukemic stem cells. Proc Natl Acad Sci U S A 2008, 105:17967-17972.
26. Hu Y, Chen Y, Douglas L, Li S: Beta-catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia. Leukemia 2009, 23:109-116.
27. Abrahamsson A, Geron I, Gotlib J, et al.: Missplicing of glycogen synthase kinase 3 beta: A potential mechanism of blast crisis chronic myeloid leukemia stem cell generation [abstract]. Blood 2007, 110:238a-239a.
28. Guzman ML, Li X, Corbett CA, et al.: Rapid and selective death of leukemia stem and progenitor cells induced by the compound 4-benzyl, 2-methyl, 1,2,4-thiadiazolidine, 3,5 dione (TDZD-8). Blood 2007, 110:4436-4444.
29. Kavalerchik E, Gotlib J, Geron I, et al.: Inhibition of chronic myelogenous leukemia stem cells with novel WNT antagonists [abstract]. Blood 2006, 108:74a.
30. Dierks C, Beigi R, Guo GR, et al.: Expansion of Bcr-Ablpositive leukemic stem cells is dependent on Hedgehog pathway activation. Cancer Cell 2008, 14:238-249.
31. Radich JP, Dai H, Mao M, et al.: Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci U S A 2006, 103:2794-2799.
32. Copland M, Pellicano F, Richmond L, et al.: BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors. Blood 2008, 111:2843-2853.
33. Pellicano F, Copland M, Jorgensen H, et al.: The farnesyltransferase inhibitor BMS-214662 selectively targets primary CML stem cells through activation of caspases [abstract]. Br J Haematol 2008, 141(Suppl 1):121.
34. Strauss AC, Chu S, Holyoake T, Bhatia R: Effective induction of apoptosis in chronic myeloid leukemia CD34+ cells by the histone deacetylase inhibitor LAQ824 in combination with imatinib [abstract]. Blood 2007, 110:312a.
35. Burgess A, Ruefli A, Beamish H, et al.: Histone deacetylase inhibitors specifically kill nonproliferating tumour cells. Oncogene 2004, 23:6693-6701.
36. Neviani P, Santhanam R, Ma Y, et al.: Activation of PP2A by FTY720 inhibits survival and self-renewal of the Ph(+) chronic myelogenous leukemia (CML) CD34+/CD38- stem cell through the simultaneous suppression of BCR/ABL and BCR/ABL-independent signals [abstract]. Blood 2008, 112:77a.
37. Neviani P, Santhanam R, Trotta R, et al.: The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell 2005, 8:355-368.
38. Neering SJ, Bushnell T, Sozer S, et al.: Leukemia stem cells in a genetically defined murine model of blast-crisis CML. Blood 2007, 110:2578-2585.
39. Komarova NL, Wodarz D: Effect of cellular quiescence on the success of targeted CML therapy. PLoS ONE 2007, 2:e990.
40. Michor F, Hughes TP, Iwasa Y, et al.: Dynamics of chronic myeloid leukaemia. Nature 2005, 435:1267-1270.
41. Roeder I, Horn M, Glauche I, et al.: Dynamic modeling of imatinib-treated chronic myeloid leukemia: Functional insights and clinical implications. Nat Med 2006, 12:1181-1184.
42. Chu S, Xu H, Shah NP, et al.: Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment. Blood 2005, 105:2093-2098.
43. Sherbenou DW, Wong MJ, Humayun A, et al.: Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib. Leukemia 2007, 21:489-493.
44. Jiang X, Saw KM, Eaves A, Eaves C: Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells. J Natl Cancer Inst 2007, 99:680-693.
45. Jiang X, Zhao Y, Smith C, et al.: Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukemia 2007, 21:926-935.
46. Jordanides NE, Jorgensen HG, Holyoake TL, Mountford JC: Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate. Blood 2006, 108:1370-1373.
47. Hiwase DK, Saunders V, Hewett D, et al.: Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: Therapeutic implications. Clin Cancer Res 2008, 14:3881-3888.
48. Brendel C, Scharenberg C, Dohse M, et al.: Imatinib mesylate and nilotinib (AMN107) exhibit high-affinity interaction with ABCG2 on primitive hematopoietic stem cells. Leukemia 2007, 21:1267-1275.
49. Larson RA, Druker BJ, Guilhot F, et al.: Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: A subanalysis of the IRIS study. Blood 2008, 111:4022-4028.
50. Picard S, Titier K, Etienne G, et al.: Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2007, 109:3496-3499.
51. Donato NJ, Wu JY, Stapley J, et al.: Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Res 2004, 64:672-677.